We would like to inform you that a new expanded genetic panel for the detection of thrombosis is available in Avicena Laboratory. Detects 12 genes polymorphisms for:
– Factor II;
– Factor V;
– Factor VII;
– Factor XIII ;
– MTHFR:677 C/T,
– MTHFR:1298 А/C
Thrombophilia is a condition of increased tendency for the formation of pathological blood clots in blood vessels, mainly as a result of the interaction of several inherited and / or acquired predisposing factors.
The tendency to develop thrombotic diseases increases significantly when hereditary factors are combined with external factors, such as: aging, male gender, obesity, surgery, trauma, hospitalization, malignancy, prolonged immobility during travel, use of oral contraceptives, estrogen therapy, etc.
People with a mutation in any of these genes are more likely to develop deep vein thrombosis or pulmonary embolism, or clogging of any blood vessel in the body. Polymorphisms of these genes are risk factors for various conditions and diseases, such as heart disease and heart attack at a younger age, stroke, preeclampsia in pregnant women and others.
Thrombophilia is also associated with an increased risk of miscarriage. Women who have this type of mutation have a 2-3 times higher risk of recurrent miscarriages
Although it is not uncommon for infections to increase the risk of blood clots, COVID-19 is associated with an unprecedented range of blood clotting disorders in diseased patients. Patients with COVID-19 experience severe and sometimes fatal blood clotting abnormalities.
Studies show that about 25% – or even up to 70% – of critically ill patients have confirmed venous thromboembolism or pulmonary embolism.
People with a mutation in one of the factors may have an increased susceptibility to thrombotic episodes, especially in diseases that affect the coagulation system, such as the SARS-CoV-2 virus (COVID-19). Therefore, timely and accurate diagnosis is crucial.
Sample: whole blood
Method: Real-Time PCR
Price of the test: 2,900.00 MKD